Company info
György Gottsegen was the founder of the Hungarian Institute of Cardiology in 1957 which was become the only centre in Hungary dedicated exclusively to cardiology. The clinical and scientific prestige of the Institute grew rapidly in Hungary and abroad necessitating a modern, more spacious building. In 1977, the Hungarian Institute of Cardiology moved to a modern new building which was already able to host the entire field of non-invasive and invasive cardiology, adult and pediatric cardiology and heart surgery as the largest cardiology centre in Hungary.
Address 1096 Budapest Haller str 29. Hungary
Tel + 36 / 1-215-1220
Website http://www.kardio.hu/index.php?lang=_2
Email titkarsag@kardio.hu
Dr. Péter Ofner, Former Director of the Gottsegen Hungarian Insititute of Cardiology, shares his insights on the cardiological capabilities of the institute, the epidemiological profile of the country, the collaborations…
A roundup of some of the top news coming out of the Central and Eastern European (CEE) region’s pharma industry, including Poland’s first draft of a national critical medicines list;…
Some of the biggest stories coming out of the Central and Eastern European (CEE) region’s pharma industry, including the European Bank’s EUR 25 million investment in Pelion Group; the amendments…
Some of the most important stories emanating from the Central and Eastern European (CEE) region’s pharma industry, including Polpharma’s bid for Zentiva, Richter’s acquisition of OC Distributors and MDD approval…
The latest pharma news from Central and Eastern Europe (CEE), including a new report on the disparities between the region’s healthcare systems and those of Western Europe; why US companies…
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to…
Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading…
According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million…
Established in 1997, Medi-Radiopharma is a Hungarian privately held company operating in the field of nuclear medicine, a specialized area of radiology that uses very small amounts of radioactive materials,…
As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations.…
Krisztina Kárpát, MD of Bayer Hungary, elaborates on the successful development of the affiliate in recent years, making progress in all three business units of pharma, consumer health, and crop…
Judit Bidlo, deputy director general of price support at the Hungarian National Health Insurance (NEAK), shares her insights on the healthcare system’s developments over the last three years, the rationale…
Among the efforts of Hungarian stakeholders to determine more efficient pricing and reimbursement structures, there is a common ambition to explore what is considered by many to be the next…
See our Cookie Privacy Policy Here
